Oral presentations colon biopsies from UC patients taken before and four weeks after local cobitolimod treatment, clearly indicated a significant induction of IL-10+ and a pronounced reduction of IL-17+ mucosal immune cells, which were not observed in the placebo group. In addition, regulatory FOXP3+ T cells (T-reg cells) were significantly increased in the colon of UC patients upon cobitolimod treatment. Conclusions: Local administration of the TLR9 agonist cobitolimod modulates the immune response in a mouse model of colitis as well as in UC patients. Our studies demonstrate that cobitolimod treatment decreases IL-17 expression and the number of Th17 cells, while it increases mucosal IL-10 expression and the quantity of T-reg cells, thus modulating the Th17/T-reg imbalance in intestinal inflammation. In conclusion, cobitolimod addresses new therapeutic targets in the immunopathogenesis of UC, leading to pronounced anti-inflammatory effects.
Background: Anti-tumour necrosis factor (anti-TNF) agents are effective agents to treat perianal Crohn's disease (CD). Recent evidence suggests that CD patients with perianal fistulas need higher serum concentrations of infliximab (IFX) compared with patients without perianal CD in order to achieve disease control. Methods: We performed a retrospective survey of all CD patients receiving active treatment with IFX or adalimumab (ADL) at our centre with available serum concentrations of IFX and ADL in CD patients with perianal fistulas. Fistula closure was defined as absence of drainage at physical examination and/or fistula healing on magnetic resonance imaging. Anti-TNF serum concentrations were compared among patients with active and closed perianal fistulas. Only patients with an interval between physical fistula examination/imaging and serum anti-TNF serum level measurement not exceeding 4 weeks were included in the analysis. Patients who underwent surgical interventions (i.e. ligation of intersphincteric fistula tract surgery or faecal diversion procedure) between physical examination/imaging and measurement of anti-TNF serum levels and patients with internal fistulas were excluded. Results: Of 352 CD patients receiving IFX or ADA, 67 had a history of perianal fistula. Forty-seven out of 67 were treated with IFX. Median IFX serum concentrations at trough ([interquartile range]) were significantly higher in patients with closed fistula (n = 32) compared with patients with active fistula (n = 15): 6.0 µg/ml [5.4-6.9] vs. 2.3 µg/ml [1.1-4.0], respectively (p < 0.001)). A similar outcome was seen in 19 of 67 patients treated with ADL (13 with closed fistula and 6 with active fistula) with median serum concentrations of 7.4 µg/ml [6.5-10.8] vs. 4.8 µg/ml [1.7-6.2] respectively; p = 0.003. There were no differences seen in IFX and ADL dose and intervals between patients with active draining fistula and closed fistula.
Conclusions:
We report an association between anti-TNF serum concentrations and fistula closure in CD patients. Dose reduction of anti-TNF in CD patients with perianal disease is contraindicated, despite quiescent luminal disease.
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Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study who failed at least one conventional therapy for UC and were naïve to biologic therapy were randomised in a 1:1:1 ratio to receive apremilast 30 mg BID (APR30), apremilast 40 mg BID (APR40), or placebo (PBO) for up to 12 weeks. The primary endpoint of the study was TMS clinical remission at Week 12. Endoscopy was read centrally by independent experts blinded to treatment allocation and time point. Results: A total of 170 patients were randomised to PBO (n = 58), APR30 (n = 57), or APR40 (n = 55). There were no differences in baseline disease characteristics, and mean baseline TMS and Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/12/supplement_1/S004/4807531 by guest on 25 January 2019
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MES were 8.3 and 2.6, respectively. A significantly higher proportion of patients treated with APR30 achieved TMS clinical remission (Δ18%) and modified Mayo score (MMS) clinical remission (Δ25%) compared with PBO. A higher proportion of patients treated with APR30 and APR40 achieved a clinical response at Week 12 compared with PBO, but the result was only significant for the APR40 treatment group. At Week 12, a significantly higher proportion of patients treated with APR30 achieved a decrease of at least one point from baseline MES (Δ32%) and an MES ≤1 (Δ32%) compared with PBO. Both APR30 and APR40 treatment groups showed a trend for a higher proportion of patients achieving histological remission, defined as a Geboes score <2, compared with the PBO group. A significantly higher proportion of patients treated with APR30 achieved mucosal healing (MES ≤1 with Geboes score <2) (Δ18%) compared with PBO. Patients treated with APR30 achieved significant improvements in percent changes from baseline in hsCRP at Weeks 4, 8, and 12 and faecal calprotectin at Weeks 2, 4, and 8 compared with PBO. A similar safety profile was seen in patients treated with APR30 and APR40.
Conclusions:
In this 12-week, phase 2 study, patients with active UC treated with APR30 had clinically meaningful improvements in symptoms, endoscopy, biomarkers, and mucosal healing compared with PBO. The observed adverse events were consistent with those expected in UC patients and were also consistent with the known safety profile of apremilast.
